U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C23H26N2O2.C4H6O4
Molecular Weight 480.5528
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SOLIFENACIN SUCCINATE

SMILES

OC(=O)CCC(O)=O.O=C(O[C@H]1CN2CCC1CC2)N3CCC4=CC=CC=C4[C@@H]3C5=CC=CC=C5

InChI

InChIKey=RXZMMZZRUPYENV-VROPFNGYSA-N
InChI=1S/C23H26N2O2.C4H6O4/c26-23(27-21-16-24-13-10-18(21)11-14-24)25-15-12-17-6-4-5-9-20(17)22(25)19-7-2-1-3-8-19;5-3(6)1-2-4(7)8/h1-9,18,21-22H,10-16H2;1-2H2,(H,5,6)(H,7,8)/t21-,22-;/m0./s1

HIDE SMILES / InChI

Molecular Formula C23H26N2O2
Molecular Weight 362.4647
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Molecular Formula C4H6O4
Molecular Weight 118.088
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including: http://www.rxlist.com/vesicare-drug.htm https://www.drugs.com/mtm/solifenacin.html http://www.wikidoc.org/index.php/Solifenacin

Solifenacin is a competitive muscarinic acetylcholine receptor antagonist. The binding of acetylcholine to these receptors, particularly the M3 receptor subtype, plays a critical role in the contraction of smooth muscle. By preventing the binding of acetylcholine to these receptors, solifenacin reduces smooth muscle tone in the bladder, allowing the bladder to retain larger volumes of urine. It is FDA approved for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency. Common adverse reactions include constipation, Xerostomia. Inhibitors of CYP3A4 may increase the concentration of Solifenacin. Vice versa, CYP3A4 Inducers decrease concentration.

CNS Activity

Curator's Comment: Known to be CNS penetrant in rat. Human data not available

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
10.0 nM [Ki]
125.0 nM [Ki]
25.0 nM [Ki]
7.73 null [pKi]
7.46 null [pKi]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
VESICARE

Approved Use

VESIcare is a muscarinic antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency. VESIcare is a muscarinic antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency (1)

Launch Date

2004
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
14.1 ng/mL
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SOLIFENACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
820 ng × h/mL
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SOLIFENACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
50.8 h
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SOLIFENACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
2%
SOLIFENACIN plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
100 mg single, oral
Highest studied dose
Dose: 100 mg
Route: oral
Route: single
Dose: 100 mg
Sources: Page: p.1028
healthy, 19-40
n = 6
Health Status: healthy
Age Group: 19-40
Sex: M
Population Size: 6
Sources: Page: p.1028
30 mg 1 times / day multiple, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: multiple
Dose: 30 mg, 1 times / day
Sources: Page: p.1029
healthy, 20-35
n = 8
Health Status: healthy
Age Group: 20-35
Sex: M
Population Size: 8
Sources: Page: p.1029
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources: Page: p.4
unhealthy
n = 1233
Health Status: unhealthy
Condition: Overactive bladder
Population Size: 1233
Sources: Page: p.4
Disc. AE: Dry mouth...
AEs leading to
discontinuation/dose reduction:
Dry mouth (1.5%)
Sources: Page: p.4
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Overactive bladder
Sources: Page: p.1
Disc. AE: Angioedema, Anaphylactic reaction...
AEs leading to
discontinuation/dose reduction:
Angioedema
Anaphylactic reaction (rare)
Sources: Page: p.1
AEs

AEs

AESignificanceDosePopulation
Dry mouth 1.5%
Disc. AE
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources: Page: p.4
unhealthy
n = 1233
Health Status: unhealthy
Condition: Overactive bladder
Population Size: 1233
Sources: Page: p.4
Angioedema Disc. AE
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Overactive bladder
Sources: Page: p.1
Anaphylactic reaction rare
Disc. AE
10 mg 1 times / day multiple, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Overactive bladder
Sources: Page: p.1
Overview

OverviewOther

Other InhibitorOther SubstrateOther Inducer







Drug as perpetrator​Drug as victimTox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Effects of YM905, a novel muscarinic M3-receptor antagonist, on experimental models of bowel dysfunction in vivo.
2001 Jul
Gateways to clinical trials.
2003 Jul-Aug
Gateways to clinical trials.
2003 Jun
Gateways to clinical trials.
2003 Nov
Drug treatment of overactive bladder: efficacy, cost and quality-of-life considerations.
2004
Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder.
2004 Feb
Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and tolterodine-controlled phase 2 dose-finding study.
2004 Jan
Comparison of in vitro selectivity profiles of solifenacin succinate (YM905) and current antimuscarinic drugs in bladder and salivary glands: a Ca2+ mobilization study in monkey cells.
2004 Jan 2
In vitro and in vivo tissue selectivity profile of solifenacin succinate (YM905) for urinary bladder over salivary gland in rats.
2004 May 25
The emerging role of solifenacin in the treatment of overactive bladder.
2004 Oct
[Urinary incontinence: new pharmacologic therapies].
2004 Oct-Dec
[Urinary incontinence: anticholinergic treatment].
2004 Oct-Dec
Solifenacin in overactive bladder: a viewpoint by Hashim Hashim.
2005
Solifenacin in overactive bladder syndrome.
2005
Overactive bladder in the elderly: a guide to pharmacological management.
2005
[Neurological aspect of the hyperactive urinary bladder syndrome].
2005
Improving the tolerability of anticholinergic agents in the treatment of overactive bladder.
2005
Solifenacin and darifenacin for overactive bladder.
2005 Aug
Recent developments in the management of overactive bladder: focus on the efficacy and tolerability of once daily solifenacin succinate 5 mg.
2005 Jan
New molecular entity: Vesicare, Yamanouchi/GlaxoSmithKline solifenacin.
2005 Jan
Improved quality of life in patients with overactive bladder symptoms treated with solifenacin.
2005 Jan
[Medical therapy of urinary incontinence].
2005 Jan
New drugs: acamprosate calcium and solifenacin succinate.
2005 Jan-Feb
Darifenacin in the treatment of overactive bladder.
2005 Jul
New treatment options for overactive bladder.
2005 Jun
Solifenacin and darifenacin for overactive bladder.
2005 Mar 14
Effect of age on the pharmacokinetics of solifenacin in men and women.
2005 May
Muscarinic receptor binding, plasma concentration and inhibition of salivation after oral administration of a novel antimuscarinic agent, solifenacin succinate in mice.
2005 May
[Drug discovery in the fields of urology: tamsulosin and solifenacin].
2005 Nov
Solifenacin versus tolterodine--a head-to-head study: finally! But not final?
2005 Nov
Solifenacin in the management of the overactive bladder syndrome.
2005 Oct
Synthesis and antimuscarinic properties of quinuclidin-3-yl 1,2,3,4-tetrahydroisoquinoline-2-carboxylate derivatives as novel muscarinic receptor antagonists.
2005 Oct 20
Role of muscarinic receptor antagonists in urgency and nocturia.
2005 Sep
A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial.
2005 Sep
Solifenacin in overactive bladder syndrome.
2006
Solifenacin significantly improves all symptoms of overactive bladder syndrome.
2006 Aug
Multiple doses of the antimuscarinic agent solifenacin do not affect the pharmacodynamics or pharmacokinetics of warfarin or the steady-state pharmacokinetics of digoxin in healthy subjects.
2006 Aug
Efficacy of solifenacin in patients with severe symptoms of overactive bladder: a pooled analysis.
2006 Jan
Re: Chapple CR, Martinez-Garcia R, Selvaggi L, Toozs-Hobson P, Warnack W, Drogendijk T, Wright DM, Bolodeoku J. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur Urol 2005;48:464-70.
2006 Jan
Comparative evaluation of exocrine muscarinic receptor binding characteristics and inhibition of salivation of solifenacin in mice.
2006 Jul
Short- and long-term efficacy of solifenacin treatment in patients with symptoms of mixed urinary incontinence.
2006 Jun
Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis.
2006 Mar
Using anticholinergics to treat overactive bladder: the issue of treatment tolerability.
2006 Mar
Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the VESIcare Open-Label Trial (VOLT).
2006 Nov
Gateways to clinical trials.
2006 Nov
Effect of antimuscarinic drugs used for overactive bladder on learning in a rat passive avoidance response test.
2007 Feb 28
Pharmacological characterization of a new antimuscarinic agent, solifenacin succinate, in comparison with other antimuscarinic agents.
2007 Jan
Solifenacin for overactive bladder with incontinence: symptom bother and health-related quality of life outcomes.
2007 Mar
An unusual cause of postoperative detrusor overactivity.
2007 Oct
Comparison of the efficacy and tolerability of solifenacin succinate with or without previous use of trospium chloride.
2007 Sep
Patents

Sample Use Guides

5 mg tablet taken once daily, and if well tolerated may be increased to 10 mg once daily.
Route of Administration: Oral
The inhibitory effect of solifenacin (dose range: 10^-10 - 10^-6 M) for bladder smooth muscle cells (pK(i)=8.12) was 3.6-fold more potent than that for salivary gland cells (pK(i)=7.57).
Substance Class Chemical
Created
by admin
on Fri Dec 15 16:33:48 GMT 2023
Edited
by admin
on Fri Dec 15 16:33:48 GMT 2023
Record UNII
KKA5DLD701
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
SOLIFENACIN SUCCINATE
JAN   MART.   MI   ORANGE BOOK   USAN   VANDF   WHO-DD  
USAN  
Official Name English
YM67905
Code English
SOLIFENACIN SUCCINATE [USAN]
Common Name English
YM905
Code English
YM-67905
Code English
SOLIFENACIN SUCCINATE [USP-RS]
Common Name English
YM-905
Code English
SOLIFENACIN SUCCINATE [EP MONOGRAPH]
Common Name English
SOLIFENACIN SUCCINATE [VANDF]
Common Name English
VESICARE LS
Brand Name English
Solifenacin succinate [WHO-DD]
Common Name English
SOLIFENACIN SUCCINATE [ORANGE BOOK]
Common Name English
SOLIFENACIN SUCCINATE [MI]
Common Name English
SOLIFENACIN SUCCINATE [JAN]
Common Name English
SOLIFENACIN SUCCINATE [MART.]
Common Name English
VESICARE
Brand Name English
Classification Tree Code System Code
NCI_THESAURUS C29704
Created by admin on Fri Dec 15 16:33:48 GMT 2023 , Edited by admin on Fri Dec 15 16:33:48 GMT 2023
Code System Code Type Description
SMS_ID
100000090370
Created by admin on Fri Dec 15 16:33:48 GMT 2023 , Edited by admin on Fri Dec 15 16:33:48 GMT 2023
PRIMARY
RXCUI
477365
Created by admin on Fri Dec 15 16:33:48 GMT 2023 , Edited by admin on Fri Dec 15 16:33:48 GMT 2023
ALTERNATIVE
NCI_THESAURUS
C73805
Created by admin on Fri Dec 15 16:33:48 GMT 2023 , Edited by admin on Fri Dec 15 16:33:48 GMT 2023
PRIMARY
DAILYMED
KKA5DLD701
Created by admin on Fri Dec 15 16:33:48 GMT 2023 , Edited by admin on Fri Dec 15 16:33:48 GMT 2023
PRIMARY
MERCK INDEX
m10108
Created by admin on Fri Dec 15 16:33:48 GMT 2023 , Edited by admin on Fri Dec 15 16:33:48 GMT 2023
PRIMARY Merck Index
PUBCHEM
216457
Created by admin on Fri Dec 15 16:33:48 GMT 2023 , Edited by admin on Fri Dec 15 16:33:48 GMT 2023
PRIMARY
EVMPD
SUB21028
Created by admin on Fri Dec 15 16:33:48 GMT 2023 , Edited by admin on Fri Dec 15 16:33:48 GMT 2023
PRIMARY
MESH
C441209
Created by admin on Fri Dec 15 16:33:48 GMT 2023 , Edited by admin on Fri Dec 15 16:33:48 GMT 2023
PRIMARY
RXCUI
476588
Created by admin on Fri Dec 15 16:33:48 GMT 2023 , Edited by admin on Fri Dec 15 16:33:48 GMT 2023
PRIMARY
DRUG BANK
DBSALT001639
Created by admin on Fri Dec 15 16:33:48 GMT 2023 , Edited by admin on Fri Dec 15 16:33:48 GMT 2023
PRIMARY
USAN
MM-33
Created by admin on Fri Dec 15 16:33:48 GMT 2023 , Edited by admin on Fri Dec 15 16:33:48 GMT 2023
PRIMARY
EPA CompTox
DTXSID30947075
Created by admin on Fri Dec 15 16:33:48 GMT 2023 , Edited by admin on Fri Dec 15 16:33:48 GMT 2023
PRIMARY
FDA UNII
KKA5DLD701
Created by admin on Fri Dec 15 16:33:48 GMT 2023 , Edited by admin on Fri Dec 15 16:33:48 GMT 2023
PRIMARY
RS_ITEM_NUM
1615300
Created by admin on Fri Dec 15 16:33:48 GMT 2023 , Edited by admin on Fri Dec 15 16:33:48 GMT 2023
PRIMARY
CAS
242478-38-2
Created by admin on Fri Dec 15 16:33:48 GMT 2023 , Edited by admin on Fri Dec 15 16:33:48 GMT 2023
PRIMARY
ChEMBL
CHEMBL1734
Created by admin on Fri Dec 15 16:33:48 GMT 2023 , Edited by admin on Fri Dec 15 16:33:48 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
PARENT -> SALT/SOLVATE
Related Record Type Details
IMPURITY -> PARENT
IMPURITY -> PARENT
IMPURITY -> PARENT
Related Record Type Details
ACTIVE MOIETY